Information Journal Paper
APA:
Copy. (2017). Sacituzumab govitecan (IMMU‐ 132), an anti‐ Trop‐ 2‐ SN‐ 38 antibody‐ drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer, 123(19), 3848-3854. SID. https://sid.ir/paper/752423/en
Vancouver:
Copy. Sacituzumab govitecan (IMMU‐ 132), an anti‐ Trop‐ 2‐ SN‐ 38 antibody‐ drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer[Internet]. 2017;123(19):3848-3854. Available from: https://sid.ir/paper/752423/en
IEEE:
Copy, “Sacituzumab govitecan (IMMU‐ 132), an anti‐ Trop‐ 2‐ SN‐ 38 antibody‐ drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics,” Cancer, vol. 123, no. 19, pp. 3848–3854, 2017, [Online]. Available: https://sid.ir/paper/752423/en